Pfizer and Hisun had signed a memorandum of understanding (MOU) in June 2011 for the establishment of the joint venture. Hisun-Pfizer, which has a registered capital of $250 million, has a total ...
Kim will now oversee product architecture, pricing, positioning, and customer experience, while continuing to lead ...
Somerset, N.J. & Taizhou City, Zhejiang Province, China — Catalent Pharma Solutions, the leading global provider of development solutions and advanced delivery technologies for drug, biologic and ...
Overview: Zhejiang Hisun Pharmaceutical Co., Ltd. is involved in the research, development, production, and sale of biological and generic drugs in China, with a market capitalization of CN¥11.31 ...
LAWRENCEVILLE, N.J. and TAIZHOU CITY, China, Jan. 22, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, and Zhejiang Hisun Pharmaceutical Company ...
China’s Zhejiang Hisun Pharmaceutical has gotten in progressively hotter water with the FDA but its troubles have not kept it from striking deals globally with other drugmakers, including one this ...
HONG KONG – China's Zhejiang Hisun Pharmaceutical Co. Ltd. said results of two key phase III trials for HS-25, a cholesterol absorption inhibitor that targets hyperlipoproteinemia, showed both met the ...
Celsion Corporation has announced that it has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. to pursue an expanded ...
TAIZHOU, China--(BUSINESS WIRE)--According to news on June 29 from Middle East News Agency, Favipiravir, the popular drug used for treating COVID-19 has shown excellent results in clinical tests. AP, ...
Pfizer Inc. (PFE), the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading Chinese pharmaceutical company, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results